AstraZeneca follows Merck’s pullback in Britain (AZN:NASDAQ)

AstraZeneca (NASDAQ:AZN) has become the latest leading drugmaker to reconsider investment options in Britain, as the Anglo-Swedish pharma giant has paused plans for a £200M (~$271M) investment in its Cambridge research site, following a similar move by Merck ( ...